{"id":15108,"date":"2025-11-04T13:19:52","date_gmt":"2025-11-04T07:49:52","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15108"},"modified":"2026-01-06T18:29:25","modified_gmt":"2026-01-06T12:59:25","slug":"curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Curis Lifesciences IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p>In November 2025, India\u2019s SME IPO space continues to stay busy, with pharma and healthcare-focused companies hitting the market to fund capacity expansion, regulatory registrations, and working capital. Riding on this momentum, Curis Lifesciences Limited is launching its <a href=\"https:\/\/www.torusdigital.com\/ipo\">IPO<\/a> on November 7, 2025, giving investors a chance to participate in a formulations and contract\/loan license manufacturing play with a growing global footprint.<\/p>\n<p>Below is a structured look at Curis Lifesciences, its IPO details, timelines, financials, and key risks\/considerations:<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Curis_Lifesciences_Ltd\"><\/span><strong>About Curis Lifesciences Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in 2010, <a href=\"https:\/\/www.torusdigital.com\/stocks\/curis-lifesciences-ltd-share-price\">Curis Lifesciences Limited<\/a> is a pharmaceutical company engaged in developing, manufacturing, and distributing a diverse range of formulations. The company manufactures for:<\/p>\n<ol>\n<li>Loan licence\/contract manufacturing for more than 100 corporate clients (India and overseas), and<\/li>\n<li>Its own brand marketing (currently 2 clients in Yemen and Kenya).<\/li>\n<\/ol>\n<h3><span class=\"ez-toc-section\" id=\"Product_basket_includes\"><\/span><strong>Product basket includes:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>General pharmaceutical tablets and capsules<\/li>\n<li>Oral liquids<\/li>\n<li>External preparations<\/li>\n<li>Sterile ophthalmic ointments<\/li>\n<\/ul>\n<p>The company operates from a state-of-the-art manufacturing facility at Sanand, Gujarat, with a focus on quality, adherence to pharma standards, and scalability.<\/p>\n<p>As of July 31, 2025, Curis Lifesciences had 95 permanent employees.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Promoters\"><\/span><strong>Promoters:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Mr. Dharmesh Dashrathbhai Patel<\/li>\n<li>Mr. Siddhant Jayantibhai Pawasia<\/li>\n<li>Mr. Piyush Gordhanbhai Antala<\/li>\n<li>Mr. Jaimik Mansukhbhai Patel<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_IPO_Details\"><\/span><strong>Curis Lifesciences IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<td>IPO Date<\/td>\n<td>November 7, 2025, to November 11, 2025<\/td>\n<\/tr>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b910\u00a0per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b9120 to \u20b9128 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>1,000 Shares<\/td>\n<\/tr>\n<tr>\n<td>Sale Type<\/td>\n<td>Fresh Capital<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>21,50,000\u00a0shares<br \/>\n(aggregating up to \u20b927.52\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Reserved for\u00a0Market Maker<\/td>\n<td>1,08,000\u00a0shares<br \/>\n(aggregating up to \u20b91.38\u00a0Cr)RS Wealth Management Private Limited<\/td>\n<\/tr>\n<tr>\n<td>Net Offered to Public<\/td>\n<td>20,42,000\u00a0shares<br \/>\n(aggregating up to \u20b926.14\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding\u00a0IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>NSE SME<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Pre Issue<\/td>\n<td>59,34,434\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Post Issue<\/td>\n<td>80,84,434\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Lead Manager<\/td>\n<td>Finaax Capital Advisors Pvt. Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Registrar<\/td>\n<td>MUFG Intime India Pvt. Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Market Maker<\/td>\n<td>RS Wealth Management Pvt. Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Important_IPO_Timeline\"><\/span><strong>Important IPO Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td>Event<\/td>\n<td>Date<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>IPO Open Date<\/td>\n<td>Fri, Nov 7, 2025<\/td>\n<\/tr>\n<tr>\n<td>IPO Close Date<\/td>\n<td>Tue, Nov 11, 2025<\/td>\n<\/tr>\n<tr>\n<td>Allotment (Tentative)<\/td>\n<td>Wed, Nov 12, 2025<\/td>\n<\/tr>\n<tr>\n<td>Initiation of Refunds<\/td>\n<td>Thu, Nov 13, 2025<\/td>\n<\/tr>\n<tr>\n<td>Credit of Shares to Demat<\/td>\n<td>Thu, Nov 13, 2025<\/td>\n<\/tr>\n<tr>\n<td>Listing Date (Tentative)<\/td>\n<td>Fri, Nov 14, 2025<\/td>\n<\/tr>\n<tr>\n<td>Cut-off time for UPI mandate confirmation<\/td>\n<td>5 PM on Nov 11, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Anchor_Portion\"><\/span><strong>Anchor Portion:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Anchor bid date: Nov 6, 2025<\/li>\n<li>Anchor shares: 6,10,000<\/li>\n<li>Anchor amount: \u20b97.81 Cr<\/li>\n<li>50% lock-in till Dec 12, 2025; balance till Feb 10, 2026<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_IPO_Reservation\"><\/span><strong>Curis Lifesciences IPO Reservation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>Investor Category<\/strong><\/td>\n<td><strong>Shares Offered<\/strong><\/td>\n<td><strong>% of Issue<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Maker<\/td>\n<td>1,08,000<\/td>\n<td>5.02%<\/td>\n<\/tr>\n<tr>\n<td>QIB<\/td>\n<td>10,18,000<\/td>\n<td>47.35%<\/td>\n<\/tr>\n<tr>\n<td>NII (HNI)<\/td>\n<td>3,08,000<\/td>\n<td>14.33%<\/td>\n<\/tr>\n<tr>\n<td>Retail (RII)<\/td>\n<td>7,16,000<\/td>\n<td>33.30%<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>21,50,000<\/td>\n<td>100.00%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_IPO_Lot_Size\"><\/span><strong>Curis Lifesciences IPO Lot Size<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors can bid for a minimum of 2 lots (2,000 shares) and thereafter in multiples of 1,000 shares.<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>Application<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount <\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Retail (Min)<\/td>\n<td>2<\/td>\n<td>2,000<\/td>\n<td>\u20b92,56,000<\/td>\n<\/tr>\n<tr>\n<td>Retail (Max)<\/td>\n<td>2<\/td>\n<td>2,000<\/td>\n<td>\u20b92,56,000<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Min)<\/td>\n<td>3<\/td>\n<td>3,000<\/td>\n<td>\u20b93,84,000<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Max)<\/td>\n<td>7<\/td>\n<td>7,000<\/td>\n<td>\u20b98,96,000<\/td>\n<\/tr>\n<tr>\n<td>B-HNI (Min)<\/td>\n<td>8<\/td>\n<td>8,000<\/td>\n<td>\u20b910,24,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_IPO_Promoter_Holding\"><\/span><strong>Curis Lifesciences IPO Promoter Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><\/td>\n<td><strong>Pre-Issue<\/strong><\/td>\n<td><strong>Post-Issue<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoter Holding<\/td>\n<td>92.68%<\/td>\n<td>68.03%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"About_Curis_Lifesciences_Business_Model_Strengths\"><\/span><strong>About Curis Lifesciences: Business Model &amp; Strengths<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Model:<\/strong> Largely contract\/loan licence manufacturing for 100+ pharma companies \u2014 meaning steady, B2B-type orders.<\/li>\n<li><strong>Own Brands:<\/strong> Early but present \u2014 currently 2 clients in Yemen and Kenya.<\/li>\n<li><strong>Location Advantage:<\/strong> Sanand, Gujarat \u2014 good infra, connectivity, and pharma ecosystem.<\/li>\n<li><strong>Why Raise Money?<\/strong> To upgrade the plant, build storage, register products abroad (a must for regulated markets), repay some loans, and fund working capital to take on more orders.<\/li>\n<\/ul>\n<p><strong>Competitive Strengths:<\/strong><\/p>\n<ul>\n<li>Experienced promoters<\/li>\n<li>Wide product basket (tabs, caps, liquids, external, ophthalmic)<\/li>\n<li>Strategic location<\/li>\n<li>Scalable model<\/li>\n<li>Quality assurance<\/li>\n<\/ul>\n<p><a href=\"https:\/\/torusdigital.go.link\/hgQeE\" target=\"_blank\" rel=\"noopener\"><br \/>\n<img decoding=\"async\" class=\"responsive-img\" src=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/07\/Desktop-1.jpg\" alt=\"\" \/><br \/>\n<\/a><\/p>\n<style>\n  .responsive-img {<br \/>\n    display: block;<br \/>\n    margin-left: auto;<br \/>\n    margin-right: auto;<br \/>\n    width: 100%;<br \/>\n    max-width: 900px;<br \/>\n<\/style>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_Ltd_Financials\"><\/span><strong>Curis Lifesciences Ltd. Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Key_Company_Financials_%E2%82%B9_in_Crore\"><\/span><strong>Key Company Financials (\u20b9 in Crore):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>31 Jul 2025<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<td><strong>31 Mar 2023<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Assets<\/td>\n<td>56.29<\/td>\n<td>42.53<\/td>\n<td>33.88<\/td>\n<td>29.75<\/td>\n<\/tr>\n<tr>\n<td>Total Income<\/td>\n<td>19.51<\/td>\n<td>49.65<\/td>\n<td>35.87<\/td>\n<td>36.42<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax<\/td>\n<td>2.87<\/td>\n<td>6.11<\/td>\n<td>4.87<\/td>\n<td>1.88<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>4.24<\/td>\n<td>9.54<\/td>\n<td>8.39<\/td>\n<td>3.28<\/td>\n<\/tr>\n<tr>\n<td>Net Worth<\/td>\n<td>19.10<\/td>\n<td>16.23<\/td>\n<td>5.87<\/td>\n<td>1.01<\/td>\n<\/tr>\n<tr>\n<td>Reserves &amp; Surplus<\/td>\n<td>13.16<\/td>\n<td>10.29<\/td>\n<td>5.37<\/td>\n<td>0.51<\/td>\n<\/tr>\n<tr>\n<td>Total Borrowing<\/td>\n<td>15.32<\/td>\n<td>15.62<\/td>\n<td>17.09<\/td>\n<td>16.19<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_KPI\"><\/span><strong>Key Performance Indicators (KPI):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>KPI<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b9103.48 Cr<\/td>\n<\/tr>\n<tr>\n<td>ROE<\/td>\n<td>55.25%<\/td>\n<\/tr>\n<tr>\n<td>ROCE<\/td>\n<td>27.83%<\/td>\n<\/tr>\n<tr>\n<td>Debt\/Equity<\/td>\n<td>0.96<\/td>\n<\/tr>\n<tr>\n<td>RoNW<\/td>\n<td>37.62%<\/td>\n<\/tr>\n<tr>\n<td>PAT Margin<\/td>\n<td>12.43%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>19.41%<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>12.64<\/td>\n<\/tr>\n<tr>\n<td>EPS (Pre IPO)<\/td>\n<td>\u20b910.29<\/td>\n<\/tr>\n<tr>\n<td>EPS (Post IPO)<\/td>\n<td>\u20b910.66<\/td>\n<\/tr>\n<tr>\n<td>P\/E (Pre IPO)<\/td>\n<td>12.44x<\/td>\n<\/tr>\n<tr>\n<td>P\/E (Post IPO)<\/td>\n<td>12.01x<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Objects_of_the_Issue_Use_of_Proceeds\"><\/span><strong>Objects of the Issue (Use of Proceeds)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>S.No.<\/strong><\/td>\n<td><strong>Objects of the Issue<\/strong><\/td>\n<td><strong>Amount (\u20b9 in Crore)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Capex for upgradation\/improvement of existing manufacturing facilities<\/td>\n<td>2.44<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Capex for the construction of a storage facility<\/td>\n<td>3.62<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Prepayment\/repayment of secured loans<\/td>\n<td>1.86<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Product registrations in other countries<\/td>\n<td>2.69<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Working capital requirements<\/td>\n<td>11.25<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>General corporate purposes<\/td>\n<td>Balance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_Industry_Outlook\"><\/span><strong>Curis Lifesciences: Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Domestic pharma continues to be driven by branded generics and export contract manufacturing.<\/li>\n<li>Loan licence \/ third-party manufacturing is attractive for medium pharma players who want asset-light expansion \u2014 this benefits companies like Curis.<\/li>\n<li>Regulatory registrations in African \/ Middle Eastern markets can materially increase the order book over 2\u20133 years.<\/li>\n<li>Being in Sanand, Gujarat, helps in logistics, manpower, and infrastructure.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Curis_Lifesciences_IPO_Peer_Comparison\"><\/span><strong>Curis Lifesciences IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.torusdigital.com\/ipo\/curis-lifesciences-ltd-ipo\">Curis Lifesciences IPO<\/a> can be compared with peers such as <a href=\"https:\/\/www.torusdigital.com\/stocks\/essen-speciality-films-ltd-share-price\">Essen Speciality Films Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/synoptics-technologies-ltd-share-price\">Synoptics Technologies Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/concord-biotech-ltd-share-price\">Concord Biotech Ltd<\/a>, Glenmark Life Sciences Ltd, and <a href=\"https:\/\/www.torusdigital.com\/stocks\/windlas-biotech-ltd-share-price\">Windlas Biotech Ltd<\/a>. Analyzing these companies helps investors assess Curis Lifesciences\u2019 relative standing in the pharmaceutical formulations and contract manufacturing segment, offering insights into its valuation, growth prospects, and competitiveness within India\u2019s rapidly expanding pharma and life sciences sector.<\/p>\n<p><strong>You may also like:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/finbud-financial-ipo-opens-key-details-investors-shouldnt-miss\/\">Finbud Financial IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/shreeji-global-fmcg-ipo-opens-key-details-investors-shouldnt-miss\/\">Shreeji Global FMCG IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/groww-ipo-opens-key-details-investors-shouldnt-miss\/\">Groww IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/studds-accessories-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\">Studds Accessories IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/safecure-services-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\">Safecure Services Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Curis Lifesciences IPO gives investors exposure to a B2B \/ contract manufacturing pharma player that has:<\/p>\n<ul>\n<li>rising revenues (38% YoY in FY25),<\/li>\n<li>healthy margins for an SME pharma (EBITDA ~19%),<\/li>\n<li>high ROE\/RONW (helped by smaller net worth so far), and<\/li>\n<li>clear use of funds (capex + storage + registrations + WC).<\/li>\n<\/ul>\n<p>However:<\/p>\n<ol>\n<li>SME listing = lower liquidity after listing<\/li>\n<li>Client concentration (100+ clients, but actual revenue may be skewed)<\/li>\n<li>Working capital\u2013heavy model<\/li>\n<li>Valuation not very cheap (P\/E ~12x for SME pharma)<\/li>\n<\/ol>\n<p>Investors with a high risk appetite and interest in SME pharma \/ CMOs can evaluate it, while conservative investors may wait for the listing and see post-listing volumes.<\/p>\n<p><span class=\"TextRun BCX8 SCXW15830496\" lang=\"EN-IN\" xml:lang=\"EN-IN\" data-contrast=\"auto\"><span class=\"NormalTextRun BCX8 SCXW15830496\">If you are exploring more investment opportunities, check out our dedicated page on <a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO listings<\/a> to stay updated on the latest market offerings.<\/span><\/span><span class=\"EOP BCX8 SCXW15830496\" data-ccp-props=\"{}\">\u00a0<\/span>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15108 \"  data-post-id=\"15108\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--half-highlight js-rmp-remove-half-star\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">3.3<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">4<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcuris-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Curis+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Curis+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcuris-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Curis+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcuris-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcuris-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Curis+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] In November 2025, India\u2019s SME IPO space continues to stay busy, with pharma and healthcare-focused companies hitting the market to fund capacity expansion, regulatory registrations, and working capital. Riding on this momentum, Curis Lifesciences Limited is launching its IPO on November 7, 2025, giving investors a chance to participate in","protected":false},"author":1,"featured_media":14024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-15108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Curis Lifesciences IPO Opens: What Investors Need to Know<\/title>\n<meta name=\"description\" content=\"Curis Lifesciences IPO is a \u20b927.52 crore SME book-built issue opening on November 7, 2025. Get the price band, lot size, reservation, financials, and objects of the issue in one place.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curis Lifesciences IPO Opens: What Investors Need to Know\" \/>\n<meta property=\"og:description\" content=\"Curis Lifesciences IPO is a \u20b927.52 crore SME book-built issue opening on November 7, 2025. Get the price band, lot size, reservation, financials, and objects of the issue in one place.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T07:49:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T12:59:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curis Lifesciences IPO Opens: What Investors Need to Know","description":"Curis Lifesciences IPO is a \u20b927.52 crore SME book-built issue opening on November 7, 2025. Get the price band, lot size, reservation, financials, and objects of the issue in one place.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Curis Lifesciences IPO Opens: What Investors Need to Know","og_description":"Curis Lifesciences IPO is a \u20b927.52 crore SME book-built issue opening on November 7, 2025. Get the price band, lot size, reservation, financials, and objects of the issue in one place.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-11-04T07:49:52+00:00","article_modified_time":"2026-01-06T12:59:25+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Curis Lifesciences IPO Opens: What Investors Need to Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","datePublished":"2025-11-04T07:49:52+00:00","dateModified":"2026-01-06T12:59:25+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Curis Lifesciences IPO is a \u20b927.52 crore SME book-built issue opening on November 7, 2025. Get the price band, lot size, reservation, financials, and objects of the issue in one place.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Curis Lifesciences IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15108"}],"version-history":[{"count":4,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15108\/revisions"}],"predecessor-version":[{"id":16089,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15108\/revisions\/16089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14024"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}